Says respond else face action Annoyed by the non-submission of reports regarding illegal clinical trials of breast cancer drug, the National Human Rights Commission (NHRC) has issued notices to the Union health ministry and the Andhra Pradesh government. It has asked the Centre and the state government to respond within six weeks or face action. The commission had in June last year sent notices to the Union health secretary, secretary of the...
More »SEARCH RESULT
Total Matching Records found : 388
The Rs 28 Diet Plan-Anuradha Raman
Trying—and failing—to live on the govt’s definition of ‘not poor’ Dietetics Of Poverty Three cups of tea, adding up to about 150 calories Two slices of bread (100 calories) Two pieces of kulcha with chhole (about 425 calories) Bread and tea hardly contain any nutrients. Milk may provide some calcium. Near-starvation diets, with hardly any vitamins or minerals, can lead to a breakdown of muscles and weight loss over a...
More »Poverty line at 28.65: Planning Commission faces criticism for figures
-PTI Planning Commission today faced criticism inside and outside Parliament for its description of poor and resultant fall in people below the poverty line with Opposition parties saying it was making a "dishonest" attempt to conceal reality through "fraudulent" estimates. BJP hit out at the government and the Planning panel for the conclusion that the number of people living below the poverty line has fallen by seven per cent, alleging that the...
More »3 years of RTI in J&K-Dr Raja Muzaffar Bhat
Today is 20th March and it was this day in 2009 when the new form of Right to Information Act (RTI Act) was enacted in J&K by Omar Abdullah led Government soon after coming to power. Prior to 2009 we had an RTI law passed by PDP Congress coalition Government headed by Mufti Mohammad Syeed in 2004 (J&K RTI Act 2004). The 2004 version of RTI Act was much weaker...
More »A historic move to make drugs affordable-G Ananthakrishnan
India's use of the compulsory licensing provision under its patents law for the first time to make the patented cancer drug Nexavar available at affordable prices is an essential, although belated step to curb the mounting cost of drugs. The grant of the licence by the Controller-General of Patents, Designs and Trade Marks to Natco Pharma for manufacture of the drug Sorafenib Tosylate (Nexavar) to treat liver and kidney cancer is...
More »
